G
Genocea Biosciences
Biotech & Life Sciences · Cambridge, United States · Founded 2006 · IPO 2014
Develops key breakthroughs in human vaccine discovery and development for antigens that induce T cell immunity MoreLess
Genocea Biosciences, based in Cambridge, is a pioneering bioscience company focused on developing personalized cancer vaccines and immunotherapies. The company operates in the biotechnology sector, specifically targeting cancer treatment through its innovative ATLAS platform. This platform identifies true T cell antigens, enabling the creation of tailored immunotherapies that are as unique as the individual cancers they target. Genocea's primary clients are cancer patients and healthcare providers seeking advanced treatment options. The company generates revenue through the development and commercialization of its proprietary cancer vaccines and immunotherapies. Genocea's business model involves extensive research and development, clinical trials, and partnerships with healthcare institutions to bring its therapies to market. The company's mission is to conquer cancer by leveraging the immune system's ability to recognize and fight cancer cells. Keywords: personalized cancer vaccines, neoantigen immunotherapies, T cell antigens, ATLAS platform, biotechnology, cancer treatment, healthcare providers, immunotherapy efficacy, clinical trials, bioscience.
Talent graph
Genocea Biosciences's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Genocea Biosciences has talent and traffic
Market sentiment
What the market is saying about Genocea Biosciences
An AI-synthesized read of the highest-engagement posts about Genocea Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genocea Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.







